Advanced Filters
noise

Neoplasms Clinical Trials

A listing of Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 14,180 clinical trials
x xiangling Wang, Dr.

Second-line Treatment of Metastatic Colorectal Cancer

The goal of this multicenter, single-arm, observational cohort study is to investigate the efficacy and safety of irinotecan in combination with trifluridine-tipiracil and bevacizumab in colorectal cancer with prior oxaliplatin and fluoropyrimidine-based chemotherapy (including 5-FU/capecitabine/S-1) exposure in the metastatic setting or within 12 months of recurrence.

18 - 75 years of age All Phase 2
g guozhu xie

Pembrolizumab Plus Radiotherapy for Advanced Renal Cancer

This study is designed as a phase-II proof of clinical trial to investigate if a treatment strategy where stereotactic body radiation therapy (SBRT) is given with pembrolizumab is sufficiently active to warrant further investigation in randomized phase II or III studies. Metastatic renal cell cancer (mRCC) patients with PD-1 expressing …

18 years of age All Phase 2
C Carlos Andres Narvaez

Dermatitis During Adjuvant Irradiation for BREAst Cancer:

In the randomized DAI-BREAC trial, a reminder app will be prospectively tested that reminds breast cancer patients four times each day to perform the required skin care. This will likely contribute to the reduction of grade ≥2 radiation dermatitis in these patients. A total of 268 patients will be randomized …

18 years of age Female Phase N/A
H Huojun Zhang, M.D.

Radical Hypofractionated Radiotherapy for Localized Prostate Cancer

The aim of this trial is to study the safety outcomes of hypofractionated radiotherapy in treating patients with localized prostate cancer. Hypofractionated radiotherapy delivers higher doses of radiotherapy in a shorter time period, may enabling the killing of more tumor cells with fewer side effects. Accumulating evidence has proven the …

18 years of age Male Phase N/A
Z Zhonghua Wang, MD

Reverse HER2-negative Immune Resistant Breast Cancer

This is a Phase II, open-label study evaluating the efficacy and safety of combined treatment (retinoic acid) with immune checkpoint inhibitor in HER2-negative breast cancer patients who progressed during previous immune checkpoint inhibitors.

18 - 70 years of age Female Phase 2
U US GSK Clinical Trials Call Center

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

The primary purpose of this study is to determine the maximum tolerated dose of GSK4524101 monotherapy (MTD) and GSK4524101 in combination with niraparib (MTDc). The study consists of two parts - Part 1 (Dose Escalation) and Part 2 (Dose Expansion).

18 years of age All Phase 1/2

A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Injection in Participants With Advanced Solid Tumors

This is an open-label, nonrandomized, multicenter, Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of MK-6204 as monotherapy in participants with advanced solid tumors.

18 years of age All Phase 1

Characterization of Hyperpolarized Pyruvate MRI Reproducibility

The purpose of the study is to test a new approach to see if the test results can be reproduced each time the Magnetic resonance imaging (MRI) is done for an individual patient. The study will explore the use of an imaging agent called hyperpolarized [1-13C] pyruvate (HP) with MRI …

21 - 90 years of age All Phase N/A

Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection

Objectives: To evaluate the safety and tolerability of BAT8006 for injection in patients with advanced solid tumors, explore the maximum tolerated dose (MTD), and provide the recommended dose for subsequent clinical trials.

18 - 75 years of age All Phase 1

Phase 1 Trial of KH617

KH617 is a injection used for advanced solid tumors which must be diluted with 5% Dextrose Injection.

18 years of age All Phase 1

Simplify language using AI